TrialCardiovascular diabetology2020

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.

Gilles R Dagenais et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.